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ABSTRACT Familial hypobetalipoproteinemia is an auto-
somal codominant disorder resulting in a dramatic reduction in
plasma concentrations of apolipoprotein (apo) B, cholesterol,
and ,-migrating lipoproteins. A benefit of hypobetalipopro-
teinemia is that mildly affected individuals may be protected
from coronary vascular disease. We have used gene targeting
to generate mice with a modified Apob allele. Mice containing
this allele display all of the hallmarks of human hypobetali-
poproteinemia: they produce a truncated apoB protein,
apoB70, and have markedly decreased plasma concentrations
of apoB, ,B-lipoproteins, and total cholesterol. In addition, the
mice manifest several characteristics that are occasionally
observed in human hypobetalipoproteinemia, including re-
duced plasma triglyceride concentrations, fasting chylomicro-
nemia, and reduced high density lipoprotein cholesterol. An
unexpected finding is that the modified Apob allele is strongly
associated with exencephalus and hydrocephalus. These mice
should help increase our understanding of hypobetalipopro-
teinemia, atherogenesis, and the eitiology of exencephalus and
hydrocephalus.
Apolipoprotein (apo) B is a major structural component of
very low density lipoprotein (VLDL), intermediate density
lipoprotein (IDL), low density lipoprotein (LDL), chylomi-
crons, and lipoprotein(a). High plasma levels of apoB-
containing lipoproteins are associated with an increased risk
of coronary artery disease (1). apoB normally exists in two
forms, apoB100 and apoB48; both are the product ofthe same
gene (2). The human gene spans 43 kb ofDNA and contains
29 exons (3).
apoBlOO, which contains 4536 amino acids, is synthesized
exclusively in the liver and is secreted into the circulation as
a surface component of triglyceride-rich VLDL. It is a ligand
for the LDL receptor and is responsible for receptor-
mediated clearance of LDL by the liver and other organs.
Amino acids 3146-3159 and amino acids 3357-3368 are
thought to be important components of the LDL receptor-
binding domain of apoBlOO (4).
apoB48 is formed as a result of post-transcriptional editing
ofapoB mRNA, which changes codon 2153 into a stop codon
(5, 6). apoB48 is synthesized in small intestine and is required
for the packaging of dietary lipids into chylomicrons. A large
percentage of mouse hepatic apoB mRNA is edited, indicat-
ing that the mouse probably makes apoB48 in the liver (D. F.
Johnson, personal communication). apoB48 lacks the puta-
tive LDL receptor-binding domain of apoBlOO and does not
interact with the LDL receptor.
In humans, many mutations in the APOB gene have been
identified that prevent the translation of full-length apoB
proteins (for reviews, see refs. 7 and 8). Such mutations cause
familial hypobetalipoproteinemia (HBL), a condition char-
acterized by a reduction in circulating apoB, cholesterol, and
,-lipoproteins. Humans homozygous for "null alleles" have
a complete absence of apoB-containing lipoproteins and can
be severely affected with symptoms of intestinal fat malab-
sorption, fat-soluble vitamin deficiency, and neurological
problems. The phenotypes of individuals homozygous for
mutant APOB alleles leading to the synthesis of truncated
apoB proteins are variable (7-10). Heterozygotes have one-
third to one-half of normal apoB and LDL-cholesterol levels
and are almost always asymptomatic. Because of their low
cholesterol levels, heterozygotes appear to be protected from
coronary vascular disease and have a longer life expectancy
(10).
Progress is being made toward understanding atherogen-
esis by investigating humans and animals that are genetically
prone to hyperlipidemia. A valid alternative is to study
humans and animals that are genetically protected from
cardiovascular disease. With this in mind, we have generated
a mouse model of HBL. To do this, we used a sequence
insertion vector to disrupt exon 26 ofthe Apob gene in mouse
embryonic stem (ES) cells. Mice carrying this disrupted gene
synthesize apoB48 and a truncated apoB (apoB70) but no
apoBlOO. The lipoprotein phenotype of the mice is remark-
ably similar to familial HBL in humans. Quite unexpectedly,
however, some of the mice also exhibit exencephalus and
hydrocephalus, pathologic features that have never, to our
knowledge, been reported in human HBL.
MATERIALS AND METHODS
Preparation of Targeting Constructs. An =l11-kb Bgl II
fragment containing exon 26 of the Apob gene was isolated
from STO cellDNA (11). Two oligonucleotides which encode
peptides of human f3s-globin (amino acids 1-12 and 120-131)
were used to replace nucleotides located in exon 26 of the
Apob gene (see Fig. 1) that encode two short amino acid
sequences thought to be important in binding to the LDL
receptor (4). An in-frame stop codon was inadvertently
inserted into the 5' 3s-globin sequence while making the
constructs, but its presence later proved beneficial to the
outcome of the experiments. 0-type (insertion) targeting
plasmids were constructed with an 8.3-kb HindIII fragment
of the Apob gene which includes the ,35-globin modifications,
an HPRT minigene [pnI2(IlS) of Reid et al. (12)], and
pBluescript (Stratagene) (Fig. 1B). Constructs were made
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FIG. 1. (A) Endogenous Apob locus, showing relative location of
sequences coding for LDL receptor-binding domains (white boxes)
within exon 26 (solid black box). The horizontal arrow illustrates the
size of the endogenous Bgl II fragment. Probe A is a 1.1-kb
HindIII/Bgl II fragment. Probe B is a 2.35-kb EcoRI fragment. (B)
Insertion type targeting construct. The sequences that encode the
LDL receptor-binding domains of the endogenous Apob locus have
been replaced with 1s-globin sequences as indicated by asterisks.
The downward arrow indicates the Sac I site used to linearize the
construct prior to electroporation. Probe C hybridizes to plasmid
vector sequences (thin line). H in stippled box indicates hypoxan-
thine phosphoribosyltransferase (HPRT) DNA. (C) Targeted Apob
locus of cell line ESapoB6-3, which contains three repeats of Apob
sequences that include the ps-globin modifications. In this locus, the
HPRT gene is in the opposite transcriptional orientation from the
Apob gene. The expected sizes of the Bgl II fragments are illustrated
with horizontal arrows. The in-frame premature translation termi-
nation codon introduced into the modified locus is illustrated (term.).
This will alter the amino acid sequence of the gene product at
positions 3142-3145 to Val-His-stop from Leu-Ser-Val-. P1 is a
Ps-globin-specific PCR primer (5'-TTACACCTCCTGTCCAAGCC-
3') and P2 is an apoB-specific PCR primer (5'-TATCAGCCAGT-
TCTTGCACG-3').
having the HPRT gene in the same (pTS5) or opposite (pTS6)
orientation as the Apob gene.
Targeting of the Apob Locus in Mouse ES Cells. Electropo-
ration of the targeting constructs into the HPRT- ES cell line
E14TG2a (13) and selection ofHPRT+ cells was as previously
described (14, 15). ES cells surviving the selection procedure
were screened for targeted recombination by PCR essentially
as described (16), using a human jBs-globin sequence-specific
primer and an Apob sequence-specific primer (see Fig. 1C).
PCR-positive ES cell colonies were expanded and genomic
DNA was prepared for Southern blot analysis. Blots were
hybridized to a 32P-labeled probe from outside the targeting
construct (probe A, Fig. 1A), to a probe from within the
targeting construct (probe B, Fig. 1A), or to a plasmid probe
(probe C, Fig. 1B).
Production of Mice with Modified Alleles ofApob. A total of
120 blastocysts were injected with one of the targeted cell
lines, ESapoB6-3. Following transfer to pseudopregnant re-
cipient females, 21 pups were born, 13 of which were
chimeric. Three male chimeras proved capable of germline
transmission of the ES cell genome when mated with
C57BL/6J mice. Offspring inheriting the ES cell genome, as
judged by coat color, were screened for the presence of the
modified Apob allele by genomic Southern hybridization
analysis of tail DNA.
Lipid, Lipoprotein, and Apolipoprotein Analysis. Morpho-
logically normal, apparently healthy mice that had survived
to adulthood were used for lipid and lipoprotein analysis.
After an overnight fast, 200-400 ,ul of blood was collected by
retro-orbital bleeding into tubes containing 0.3 mg of EDTA,
25 mg of gentamycin sulfate, and 11.5 milliunits of aprotinin
(Sigma). Plasma was collected by centrifugation at 14,000 x
g for 10 min at 4°C. Agarose gel electrophoresis of whole
plasma and determination of total cholesterol, high density
lipoprotein (HDL) cholesterol, and triglyceride were as pre-
viously described (17, 18).
Lipoproteins were fractionated by sequential density ul-
tracentrifugation (18). Fractions were concentrated and de-
salted by using a Centricon-10 (Amicon) apparatus according
to the manufacturer's protocol, and 20 ,ug of protein from
each fraction was electrophoresed on an SDS/3-20% poly-
acrylamide gradient gel (16 x 16 x 1.5 mm) at 150 V for 6 hr
(18). The size of lipoproteins in the d (density) < 1.006 g/ml
fraction of mouse plasma was assessed by electron micros-
copy (19). Whole plasma apoAI concentrations were quan-
tified by nonreducing gel electrophoresis as described by
France et al. (20).
Northern Blot Analysis. Total RNA was prepared, electro-
phoresed, transferred to Hybond-N (Amersham), and hy-
bridized as described (21). Probes used include probes A, B,
C (see Fig. 1), apoAl (22), and human j3actin (Clontech).
RESULTS AND DISCUSSION
Targeting of the Apob Locus in Mouse ES Cells. The scheme
of targeting of the Apob locus is illustrated in Fig. 1. A total
of 1967 HPRT+ ES cell colonies were screened by PCR for
homologous recombination at the Apob locus. From 23
PCR-positive colonies, 6 lines ofES cells were established in
which targeting at the Apob locus was confirmed by Southern
blot analysis (Fig. 2). Probe A, which is external to the
targeting DNA, detected an 11-kb Bgl II fragment from the
unaltered endogenous Apob gene in all cells. In correctly
targeted ES cells, an additional Bgl II band of 12 or 12.5 kb
was detected, depending on the orientation ofthe HPRT gene
in the targeting constructs (Fig. 2A). In addition to these
bands, we also detected, with probe B, a 16.0- or 16.5-kb
fragment (depending on the orientation of HPRT) and a
17.5-kb Bgl II fragment in all six targeted cell lines (Fig. 2B).
The size of this largest fragment and its intensity indicated
that multiple tandem copies of the targeting construct had
been integrated (see Fig. 1C). Such tandem incorporation of
multiple copies of incoming DNA into a targeted locus has
been reported by others (15, 23, 24).
All Repeats in the Modified Apob Locus Have the 3Ss-Globin
Modification. One of the targeted cell lines, ESapoB6-3, was
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cu ESapoB c ESapoB






FIG. 2. Southern blot analysis of Bgl II-digested DNA from
targeted cell lines. E14TG2a is the parental ES cell line. ESapoB cell
lines 6-3, 10-2-3, and 5D2 were derived from targeting construct
pTS6. The ESapoB cell line 19-1 was derived from the targeting
construct pTS5. The differences in the size of bands between these
cell lines reflect differences in the targeting constructs. (A) Blot was
hybridized with probe A. The sizes ofA phageDNA molecular weight
standards are indicated (in kb) to the left. (B) Same blot as in A after
rehybridization with probe B.
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used to generate animals, and the structure of the modified
locus was determined by using DNA isolated from mice
homozygous for the alteration. By PCR amplification fol-
lowed by restriction enzyme digestion of the PCR products,
we were able to establish (data not shown) that ESapoB6-3
contains three repeats of Apob sequences at the targeted
locus, each having LDL receptor-binding domains that have
been changed to Is-globin sequences (Fig. 1C).
Since a stop codon is present in all three of the 5' 3s-globin
sequences, this modified Apob allele should always produce
a transcript that contains this premature translation termina-
tion codon at position 3145 (human equivalent) even if
alternative splicing of the mRNA occurs. It should not have
a leaky phenotype such as has been suggested to occur after
disruption of the N-myc (25) and cystic fibrosis (26) genes;
rather it should result in an apoB protein approximately 70%
the size of apoBlOO. The translation termination codon
should not alter the size of apoB48.
A Truncated ApoB, ApoB70, Is Produced from the Modified
Allele. SDS/polyacrylamide gel electrophoresis of the VLDL
and IDL/LDL fractions from wild-type mice reveals apoB48
and apoBlOO (Fig. 3). In contrast, the VLDL and IDL/LDL
fractions from homozygous mutants contain no detectable
apoBlOO; only apoB48 and a truncated apoB are observed.
We estimate the size of this truncated apoB protein to be
-70% the size ofapoB100 on the basis of the observation that
the truncated apoB migrates slightly faster than human
apoB74, a proteolytic product of apoBlOO (data not shown).
We will refer to the truncated apoB as apoB70. The VLDL
and IDL/LDL fractions from heterozygous mice contain all
three apoB proteins, B48, B70, and B100. It should be noted
that in the IDL/LDL fraction from heterozygous mice, the
amount of apoB70 is approximately 9% the amount of
apoBlOO. Also, in heterozygous mice the amount of apoB48
relative to apoBlOO is increased. This parallels similar ob-
servations in humans who are heterozygotes for apoB67 and
apoB83 mutations (27, 28). We estimate that apoB48 levels in
homozygous mice are reduced by one-half relative to normal.
The intensities of staining of apoB48 in the IDL/LDL frac-
tions of wild-type and homozygous mice are nearly equal in
Fig. 3, but twice the amount of sample was loaded in the
latter. Thus, our apoB mutation results in the production of
VLDL IDL/LDL HDL






a small amount of apoB70, and about half the normal amount
of apoB48. This finding is identical to the situation in humans
with HBL, where truncated apoB proteins are invariably
present in very low concentrations (7).
To investigate the mechanism responsible for the reduced
amount ofplasma apoB proteins, we examined the amount of
apoB mRNA in small intestine and liver. This analysis
showed that wild-type and heterozygous mice have similar
amounts of apoB mRNA (Fig. 4A); in contrast, the amounts
of apoB mRNA in small intestine and liver of homozygous
mice are only 25% and 40%, respectively, of the amounts in
wild-type or heterozygous mice, as estimated by densitom-
etry of the Northern blot. The size of the apoB mRNA (=14
kb) transcribed from the modified allele is similar to that from
the unmodified allele. However, probe A, which is 3' to the
site of insertion of the targeting construct, does not hybridize
to the apoB message from homozygous mice (Fig. 4B), and
probe C, which detects plasmid-related sequences, hybrid-
izes to mRNA from heterozygous and homozygous mice only
(Fig. 4C). Thus, the transcript of the mutant allele appears to
terminate in the inserted DNA. Therefore, the modified and
unmodified alleles produce distinctly different transcripts
even though the sizes appear similar. The difference in the
level of the mutant apoB mRNA could be the result of
differences in mRNA stability caused by the inserted se-
quences and/or insertional disruption of (unknown) tran-
scriptional regulatory sequences. Irrespective of the cause of
the reduced quantity of apoB mRNA, it is at least one factor
that leads to the reduced amount of apoB proteins in mice
homozygous for the modified Apob allele.
HBL in Mice Homozygous for the Modified Apob Allele.
Agarose gel electrophoresis of total plasma from wild-type
mice shows that the majority of plasma lipoproteins migrate
as three distinct bands at the a, f, and pre-13 positions (Fig.
5). Electrophoresis of total plasma from the homozygous















FIG. 3. SDS/PAGE of apolipoproteins isolated from VLDL,
IDL/LDL, and HDL fractions of wild-type (+/+), heterozygous
(+/-), and homozygous (-/-) mouse plasma. Molecular mass is
indicated on the right in kDa. The positions of apoBlOO, apoB70,
apoB48, apoE, and apoAl are indicated to the left. An amount ofeach
lipoprotein fraction was loaded that is equivalent to the amount of
plasma (in Al) shown below each lane. The identity of the apoB
proteins was confirmed by Western blotting using two different
apoB-specific antibodies (data not shown).
FIG. 4. Northern blot analysis of total RNA from small intestine
(20 ug of RNA per lane) and liver (10 ,ug of RNA per lane) from
wild-type (+/+), heterozygous (+/-), and homozygous (-/-)
mice. (A) Northern blot hybridized with probe B. The size (in kb) of
RNA standards is illustrated to the left. (B) Same blot as in A, after
rehybridization with probe A (hybridizes to apoB sequences that are
3' of the insertion site of the targeting construct). The sizes of the
bands are the same as those in A. (C) Same blot as in A, after
rehybridization with probe C (recognizes plasmid sequences). The
sizes of the bands are the same as those in A. (D) Same blot as in A,
after rehybridization with an apoAl probe. (E) Same blot as in A,
after rehybridization with a human 3-actin probe. This probe was
used to assess the integrity of the RNA preparation and to serve as
a control for the amount of RNA loaded.
Medical Sciences: Homanics et al.
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FIG. 5. Agarose gel electrophoresis of total plasma. The gel was
stained with fat red 7B. The samples analyzed are from mice that are
wild type (+/+), heterozygous (+/-), or homozygous (-/-) with
respect to the targeted Apob locus, from a normal human, and from
a human who is an apoB37/apoB86 compound heterozygote (9, 29).
Mouse plasma was obtained after a 20-hr fast; the human plasma was
obtained after a 14-hr fast. The locations of a-lipoproteins, pre-,-
lipoproteins, 3-lipoproteins, and chylomicrons (C) are indicated to
the left and to the right for mouse plasma and human plasma,
respectively.
The f3lipoproteins are also reduced in heterozygous mice,
but less markedly. A reduction in p-lipoproteins is a defining
characteristic of HBL in humans (Fig. 5).
Agarose gel electrophoresis of the plasma also reveals that
fasted homozygous mice have chylomicronemia, as evidenced
by accumulation of stained lipids at the origin of the gel (Fig.
5). This finding is not observed in heterozygous or wild-type
mice. Steinberg and co-workers (9) have reported fasting
chylomicronemia in a human with HBL; and plasma from
Steinberg's human subject, a compound heterozygote with
one mutant allele yielding apoB37 and another mutant allele
yielding apoB86 (29), is compared with the mouse plasma in
Fig. 5 to illustrate this. The cause of the fasting chylomicro-
nemia in the homozygous mice or in the human compound
heterozygote is not immediately obvious. Since neither the
targeted modification that we created nor the apoB86 mutation
of Steinberg's patient is expected to interfere with the function
of apoB48, it might be expected that chylomicrons would be
packaged, transported, and metabolized normally. It is im-
portant to note that the lipoproteins at the origin ofthe agarose
gel may not be "chylomicrons" but instead may be hepatic
lipoproteins or a mixture of hepatic and intestinal lipoproteins.
This topic warrants further investigation.
The finding of chylomicronemia led us to examine, by
electron microscopy, the size distribution of lipoprotein par-
ticles with densities less than 1.006 g/ml. The fractions oflarge
particles (>70 nm) in wild-type, heterozygous, and homozy-
gous mice were 0.8%, 0.6%, and 1.8%, respectively. The mean
(±SD) diameters of the d < 1.006 g/ml particles in wild-type,
heterozygous, and homozygous mice were virtually identical:
41.34 ± 9.56, 38.98 ± 9.26, and 39.66 ± 9.64 nm, respectively.
Thus, similar to human apoB37/apoB86 compound heterozy-
gotes (9), homozygous mutant mice also have a normal VLDL
diameter but a skewing toward larger particles.
The modified Apob allele affects circulating concentrations
of cholesterol in a co-dominant manner (Table 1). The
concentrations of total and HDL cholesterol in the plasma of
fasted homozygous mice are reduced to =50% of the normal
levels. The concentrations of total and HDL cholesterol in
heterozygous mice are also significantly less than that in
wild-type mice. The reduction of HDL cholesterol levels in
homozygous mice is also reflected in a reduction in apoAI
levels of -45% as determined by nonreducing gel electro-
phoresis of whole plasma (data not shown). Since apoAl is
the major protein component of HDL, the reduced levels of
apoAI could possibly account for the reduced HDL choles-
terol levels. However, we noted that the amount of apoAI
mRNA is not reduced in homozygotes and may even be
increased in small intestine (Fig. 4D). Thus, increased ca-




Genotype (n) cholesterol cholesterol triglyceride
Wild type (17) 111.2 ± 24.1 76.9 ± 13.1 56.9 ± 29.4
Heterozygous (16) 87.6 ± 14.7 63.1 ± 11.6 41.3 ± 17.0
P < 0.005* P < 0.005* P < 0.05*
Homozygous (16) 50.6 ± 12.8 41.4 ± 12.6 38.5 ± 13.8
P < 0.0005*t P < O.OOO5*t P < 0.025*
All values are expressed ±SD. Concentrations were compared
between genotypes by Student's t test. *, Values differ from wild
type; t, values differ from heterozygous.
tabolism of HDL (and apoAI) may be responsible for the
reductions in HDL cholesterol and apoAI. In human HBL
homozygotes, HDL concentrations have been variable, rang-
ing from low to elevated (7-10).
The concentration of triglyceride in plasma is also reduced
in a dominant manner by the modified Apob allele (Table 1).
A reduction in plasma triglycerides in human heterozygotes
has been observed in many studies (27, 30, 31).
Exencephalus and Hydrocephalus Are Associated with the
ModifiedApob Allele. During our analysis of the genotypes of
21-day-old mice from heterozygote crosses, we noted signif-
icantly fewer homozygotes than expected based on the 1:2:1
Mendelian ratios of wild type:heterozygotes:homozygotes.
We observed 108 wild-type mice, 239 heterozygotes, and
only 58 homozygotes (X2 = 25.5, P < 0.0001). To investigate
the reason for the deficiency of homozygotes, we examined
47 fetuses (day 15.5-19.5 of gestation) derived from mating
homozygous males with heterozygous females. Thirteen
were exencephalic; all proved homozygous for the modified
Apob allele. Thus, the deficiency of homozygotes at weaning
appears to be due to perinatal mortality associated with
exencephalus.
Some mice that survive to weaning develop hydrocepha-
lus. This abnormality is characterized externally by a large,
dome-shaped head that is usually detected between 3 and 6
weeks of age. Gross dissection and histological analysis of
the brain of several of the hydrocephalic mice indicate that
fluid accumulation is confined to the lateral and third ven-
tricles. Genotype analysis reveals that by 8 weeks of age,
hydrocephalus is detected in 32% (24/75) of homozygotes, in
1% (3/234) of heterozygotes, and in 0o (0/91) of wild-type
littermates. Unaffected homozygotes usually survive to ma-
turity, appear healthy, and reproduce, but some of their
offspring can be exencephalic or hydrocephalic.
Exencephalus and hydrocephalus have not been reported
in humans with abetalipoproteinemia or HBL and, at this
stage, we have no direct evidence that abnormalities in lipid
metabolism are the cause of the morphological abnormalities
in our mice. For example, since only one targeted ES cell line
was used to generate animals, we cannot exclude the possi-
bility that a mutation was introduced in an unidentified gene
that is linked to the Apob locus. It is also conceivable that
overexpression of the HPRT genes introduced into the Apob
locus affects purine metabolism during development. It is
also possible that insertion of 35 kb of DNA into the Apob
locus has affected the function of nearby genes involved in
development of the brain. However, the most plausible
explanation of these morphological abnormalities is that they
are caused by deficiency of one or more fat-soluble vitamins
that is secondary to the lack of LDL. For example, vitamin
E is a lipid-soluble vitamin that is transported in the body as
part of LDL. Humans with abetalipoproteinemia and human
HBL homozygotes often manifest clinical symptoms of vi-
tamin E deficiency (10). This deficiency leads to neuromus-
Proc. Natl. Acad. Sci. USA 90 (1993)
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cular and retinal degeneration and can be alleviated by
massive oral supplementation with vitamin E. In laboratory
animals, maternal vitamin E deficiency has been shown to
cause exencephalus and hydrocephalus in offspring (32, 33),
and we have preliminary data indicating that our adult
homozygous mice have plasma levels of a-tocopherol ap-
proximately 35% of those observed in wild-type mice
(G.E.H. and M. Traber, unpublished observations). The
effects of the Apob gene modification on the metabolism of
fat-soluble vitamins in these mice bear further investigation.
Conclusion. We have used gene targeting in ES cells to
create a mouse model of familial HBL. The HBL mice
manifest the hallmarks that define this condition in humans.
They have very low concentrations of cholesterol and the
j-lipoproteins, and they synthesize a truncated form of apoB.
All apoB proteins are present in very low levels in the plasma.
The mice also exhibit several characteristics observed in some
HBL humans: reduced HDL cholesterol levels, reduced
plasma triglyceride concentrations, fasting chylomicronemia,
and symptoms suggesting vitamin E deficiency. Therefore,
these mice represent a useful model for investigating how
truncated apoB proteins alter lipoprotein metabolism.
HBL mice will be a useful model for investigating the
effects of this condition on the development of atherogenesis.
The lipoprotein profile in these mice is expected to be
protective from fatty streak formation and atherosclerosis.
This mouse model will permit us to test this expectation by
using a genetic approach. Mice with HBL can be mated with
mice carrying mutations in additional genes involved in
lipoprotein metabolism. For example, mice homozygous for
a disrupted Apoe allele are hypercholesterolemic and spon-
taneously develop atherosclerotic lesions (18, 34). It will be
of great interest to evaluate whether the dominant effect of
the Apob gene modification will overcome the effect of the
apoE deficiency in mice with combined defects and protect
them from hyperlipidemia and atherosclerosis. Information
gained from studying this animal model of HBL could even-
tually lead to therapies (drug and/or gene) to inhibit the
atherosclerosis disease process.
We also observed that the modified Apob allele is strongly
associated with the morphological abnormalities exenceph-
alus and hydrocephalus. This may be the first example of a
known genetic alteration that causes, probably indirectly, the
congenital abnormalities exencephalus and hydrocephalus.
While all forms of these abnormalities are unlikely to be due
to changes in the Apob gene itself, a portion of them could be
due to disturbances in lipid metabolism. The regular devel-
opment of exencephalus and hydrocephalus in these mice
provides a model for investigating the development and the
pathogenesis of a disorder that affects a substantial number
of human newboms.
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